0001452804 false --09-30 2022 Q2 P1Y11M12D P1Y11M12D P1Y11M12D P1Y11M12D P1Y6M14D P1Y6M14D P1Y6M14D P1Y6M14D 0001452804 2021-10-01 2022-03-31 0001452804 2022-12-16 0001452804 2022-03-31 0001452804 2021-09-30 0001452804 2022-01-01 2022-03-31 0001452804 2021-01-01 2021-03-31 0001452804 2020-10-01 2021-03-31 0001452804 us-gaap:CommonStockMember 2020-09-30 0001452804 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001452804 us-gaap:RetainedEarningsMember 2020-09-30 0001452804 2020-09-30 0001452804 us-gaap:CommonStockMember 2021-09-30 0001452804 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001452804 us-gaap:RetainedEarningsMember 2021-09-30 0001452804 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001452804 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001452804 2020-10-01 2020-12-31 0001452804 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001452804 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001452804 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001452804 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001452804 2021-10-01 2021-12-31 0001452804 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001452804 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001452804 us-gaap:CommonStockMember 2020-12-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001452804 us-gaap:RetainedEarningsMember 2020-12-31 0001452804 2020-12-31 0001452804 us-gaap:CommonStockMember 2021-03-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001452804 us-gaap:RetainedEarningsMember 2021-03-31 0001452804 2021-03-31 0001452804 us-gaap:CommonStockMember 2021-12-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001452804 us-gaap:RetainedEarningsMember 2021-12-31 0001452804 2021-12-31 0001452804 us-gaap:CommonStockMember 2022-03-31 0001452804 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001452804 us-gaap:RetainedEarningsMember 2022-03-31 0001452804 pkph:EntityControllerBySoleOfficerAndDirectorMember 2022-03-31 0001452804 pkph:EntityControllerBySoleOfficerAndDirectorMember 2021-09-30 0001452804 pkph:ConvertibleNotesPayable1Member 2017-03-17 0001452804 pkph:ConvertibleNotesPayable1Member 2022-03-31 0001452804 pkph:ConvertibleNotesPayable1Member 2021-09-30 0001452804 pkph:ConvertibleNotesPayable2Member 2017-03-30 0001452804 pkph:ConvertibleNotesPayable2Member 2022-03-31 0001452804 pkph:ConvertibleNotesPayable2Member 2021-09-30 0001452804 pkph:NotesPayable1Member 2018-01-10 0001452804 pkph:NotesPayable1Member 2022-03-31 0001452804 pkph:NotesPayable1Member 2021-09-30 0001452804 pkph:NotesPayable2Member 2018-04-02 0001452804 pkph:NotesPayable2Member 2022-03-31 0001452804 pkph:NotesPayable2Member 2021-09-30 0001452804 pkph:NotesPayable3Member 2021-06-14 0001452804 pkph:NotesPayable3Member 2022-03-31 0001452804 pkph:NotesPayable3Member 2021-09-30 0001452804 pkph:NotesPayable4Member 2021-09-30 0001452804 pkph:NotesPayable4Member 2022-03-31 0001452804 pkph:NotesPayable5Member 2021-09-30 0001452804 pkph:NotesPayable5Member 2022-03-31 0001452804 pkph:EmployeeMember 2021-10-01 2022-03-31 0001452804 pkph:NonEmployeeMember 2021-10-01 2022-03-31 0001452804 pkph:EmployeeMember 2022-03-31 0001452804 pkph:EmployeeMember 2021-09-30 0001452804 pkph:EmployeeMember 2020-10-01 2021-03-31 0001452804 pkph:NonEmployeeMember 2022-03-31 0001452804 pkph:NonEmployeeMember 2021-09-30 0001452804 pkph:NonEmployeeMember 2020-10-01 2021-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended ~~June~~March 3031, ~~2018~~2022

¨ o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _________ to _________

Commission file number: 005-87668

PEAK PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada		26-1973257
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

14201 N. Hayden Road, Suite A-1, Scottsdale, AZ 85260

(Address of principal executive offices)

(480) 659-6404

(Registrant’s telephone number, including area code)

~~700~~ N~~. Colorado Blvd., #734, Denver, CO 80206~~/A

(Former address of principal executive offices)

~~Indicate by check mark whether the registrant~~Securities ~~(1)~~registered ~~has~~pursuant ~~filed all reports required~~ to ~~be filed by~~ Section ~~13 or 15~~12(db) of the ~~Securities Exchange~~ Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨:

~~Indicate~~Title ~~by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405~~ of ~~Regulation~~each ~~S-T~~class Trading symbol(§s) ~~232.405~~Name of ~~this~~exchange ~~chapter)~~on ~~during~~which ~~the~~registered ~~preceding~~None 12None ~~months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No þ~~None

~~Indicate by check mark whether the registrant~~Securities isregistered apursuant ~~large~~to ~~accelerated~~section ~~filer,~~12(g) ~~an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions~~ of ~~“large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of~~ the ~~Exchange~~ Act.:

~~Large~~Shares of ~~accelerated~~common ~~filer~~stock owith ~~Accelerated filer o Non-accelerated filer o Smaller reporting company þ (Do not check if~~ a ~~smaller~~par ~~reporting~~value ~~company)~~of ~~Emerging growth company □ o~~$0.0001

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) Title of ~~the Exchange Act. ¨~~class)

Indicate by check mark ~~whether~~if the registrant is a ~~shell~~well-known ~~company~~seasoned (issuer, as defined in Rule ~~12b-2~~405 of the ~~Exchange~~Securities Act). Yes ¨o No þ.x

AsIndicate by ofcheck ~~August~~mark ~~13,~~if ~~2018,~~the ~~there~~registrant ~~were~~is ~~78,363,562~~not ~~shares~~required ofto ~~registrant’s common~~file ~~stock~~reports ~~outstanding~~pursuant to Section 13 or Section 15(d) of the Act. Yes o No x

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes o No x

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes o No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o	Accelerated filer o

Non-accelerated filer x	Smaller reporting company x

	Emerging growth company o

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No o

The number of shares outstanding of the registrant’s common stock as of December 16, 2022 was 78,363,567.

PEAK PHARMACEUTICALS, INC.

FORM 10-Q

FOR THE THREE AND ~~NINE~~SIX MONTHS ENDED ~~JUNE 30~~MARCH 31, ~~2018~~2022 ~~AND~~and ~~2017~~2021

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION
PART I.	FINANCIAL INFORMATION
ITEM 1	Financial Statements	3
ITEM 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of June 30, 2018 (unaudited) and September 30, 2017	3
	Condensed Consolidated Balance Sheets as of March 31, 2022 and September 30, 2021	3
	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended June 30, 2018 and 2017 (unaudited)	4
	Condensed Consolidated Statements of Operations for the Three and Six Months Ended March 31, 2022 and 2021	4
	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended June 30, 2018 and 2017 (unaudited)	5
	Condensed Consolidated Statements of Stockholders’ Deficit for the Three and Six Months Ended March 31, 2022 and 2021	5
	Notes to Condensed Consolidated Financial Statements (unaudited)	6
	Condensed Consolidated Statements of Cash Flows for the Six Months Ended March 31, 2022 and 2021	6
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
	Notes to Condensed Consolidated Financial Statements	7
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	15
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
ITEM 4.	Controls and Procedures	15
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	16
PART II. OTHER INFORMATION
ITEM 4.	Controls and Procedures	16
ITEM 1.	Legal Proceedings	17
PART II.	OTHER INFORMATION
ITEM 1A.	Risk Factors	17
ITEM 1.	Legal Proceedings	18
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17
ITEM 1A.	Risk Factors	18
ITEM 3.	Defaults Upon Senior Securities	17
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18
ITEM 4.	Mine Safety Disclosures	17
ITEM 3.	Defaults Upon Senior Securities	18
ITEM 5.	Other Information	17
ITEM 4.	Mine Safety Disclosures	18
ITEM 6.	Exhibits	18
ITEM 5.	Other Information	18
SIGNATURES		19
ITEM 6.	Exhibits	19
SIGNATURES		20

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PEAK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

~~AS OF JUNE 30, 2018~~(Unaudited)

(Unaudited)

	March 31,			September 30,
	2022			2021
Assets
Current assets:
Cash	$	176,081		$	261,152
Prepaid expenses		4,125			-
Total Assets	$	180,206		$	261,152

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable (including $133,674 and $133,986 due to related parties)	$	203,381		$	214,136
Accrued liabilities		108,928			35,201
Convertible notes payable		10,000			20,000
Notes payable		263,000			283,000
Notes payable – related party		35,000			35,000
Total Liabilities		620,309			587,337

Stockholders’ deficit
Preferred stock, $0.0001 par value, 25,000,000 authorized, none issued or outstanding		-			-
Common stock, $0.0001 par value, 300,000,000 shares authorized, 78,363,567 shares issued and outstanding		7,836			7,836
Additional paid in capital		4,855,566			4,855,566
Accumulated deficit		(5,303,505	)		(5,189,587	)
Total Stockholders’ Deficit		(440,103	)		(326,185	)
Total Liabilities and Stockholders’ Deficit	$	180,206		$	261,152

	June 30,		September 30,
	2018		2017
			(Audited)
Assets
Current assets:
Cash	$	17,359	$	2,991
Total Assets	$	17,359	$	2,991
Liabilities and stockholders' deficit
Liabilities
Accounts payable	$	149,742	$	163,075
Accrued liabilities		13,727		7,601
Convertible notes payable		25,000		25,000
Note payable		43,000
Total Liabilities		231,469		195,676
Stockholders’ Deficit
Preferred stock, $0.00001 par value, 25,000,000 authorized, none issued or outstanding		-		-
Common stock, $0.0001 par value, 325,000,000 shares authorized, 78,363,562 shares issued and outstanding, as of June 30, 2018 and September 30, 2017		7,836		7,836
Additional paid in capital		4,855,566		4,855,566
Accumulated deficit		(5,077,511)		(5,056,087)
Total Stockholders’ Deficit		(214,109)		(192,685)
Total Liabilities and Stockholders’ Deficit	$	17,359	$	2,991

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

~~See the accompanying notes to the condensed consolidated financial statements~~ 3

~~The~~PEAK ~~accompanying~~PHARMACEUTICALS, ~~footnotes~~INC. ~~are~~CONDENSED anCONSOLIDATED ~~integral~~STATEMENTS ~~part of~~OF ~~these~~OPERATIONS ~~condensed consolidated financial statements.~~(Unaudited)


	For the Three Months Ended						For the Six Months Ended
	March 31,						March 31,
	2022			2021			2022			2021
Operating expenses:
General and administrative (including fees paid to related party of $3,279 and $22,848, and $8,049 and $27,578, for the three and six months ended March 31, 2022 and 2021)	$	46,561		$	43,243		$	98,624		$	48,215
Total operating expenses		46,561			43,243			98,624			48,215

Operating loss		(46,561	)		(43,243	)		(98,624	)		(48,215	)

Other expenses (income):
Interest expense (including related party interest of $863 and $0, and $995 and $0, for the three and six months ended March 31, 2022 and 2021, respectively)		8,002			2,498			16,833			4,880
Gain on forgiveness of debt		-			(3,029	)		(1,539	)		(3,029	)
Total other expenses (income), net		8,002			(531	)		15,294			1,851

Net loss	$	(54,563	)	$	(42,712	)	$	(113,918	)	$	(50,066	)

Per share information:
Weighted average shares outstanding - basic and diluted		78,363,567			78,363,567			78,363,567			78,363,567

Net loss per share - basic and diluted	$	(0.00	)	$	0.00		$	(0.00	)	$	(0.00	)

~~PEAK~~The accompanying ~~PHARMACEUTICALS,~~footnotes ~~INC~~are an integral part of these unaudited condensed consolidated financial statements.

~~CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS~~4

PEAK PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT FOR THE THREE AND ~~NINE~~SIX MONTHS ENDED ~~JUNE 30~~MARCH 31, ~~2018~~2022 AND ~~2017~~2021 (Unaudited)

(Unaudited)


	Common Stock				Additional Paid		Accumulated
	Shares		Amount		In Capital		Deficit			Total

Balance, October 1, 2020		78,363,567	$	7,836	$	4,855,566	$	(5,113,498	)	$	(250,096	)

Net loss		-		-		-		(7,354	)		(7,354	)
Balance, December 31, 2020		78,363,567		7,836		4,855,566		(5,120,852	)		(257,450	)

Net loss		-		-		-		(42,712	)		(42,712	)
Balance, March 31, 2021		78,363,567	$	7,836	$	4,855,566	$	(5,163,564	)	$	(300,162	)


Balance, October 1, 2021		78,363,567	$	7,836	$	4,855,566	$	(5,189,587	)	$	(326,185	)

Net loss		-		-		-		(59,355	)		(59,355	)
Balance, December 31, 2021		78,363,567		7,836		4,855,566		(5,248,942	)		(385,540	)

Net loss		-		-		-		(54,563	)		(54,563	)
Balance, March 31, 2022		78,363,567	$	7,836	$	4,855,566	$	(5,303,505	)	$	(440,103	)

	For the Three Months Ended				For the Nine Months Ended
	June 30,				June 30,
	2018		2017		2018		2017
Operating expenses:
General and administrative	$	2,998	$	14,037	$	18,208	$	21,350
Interest expense		1,286		598		3,094		634
Total expenses		4,284		14,635		21,302		21,984
Operating income (loss)		(4,284)		(14,635)		(21,302)		(21,984)
Change in fair value of convertible debt		-		-		-		(5,000)
Net loss	$	(4,284)	$	(14,635)	$	(21,302)	$	(26,984)
Per share information:
Basic weighted average shares outstanding		78,363,562		78,363,562		78,363,562		78,363,562
Diluted weighted average shares outstanding		78,363,562		78,363,562		78,363,562		78,363,562
Net loss per share - basic and diluted	$	0.00	$	0.00	$	0.00	$	0.00

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

~~See the accompanying notes to the condensed consolidated financial statements~~ 5

~~The~~PEAK ~~accompanying~~PHARMACEUTICALS, ~~footnotes~~INC. ~~are~~CONDENSED anCONSOLIDATED ~~integral~~STATEMENTS ~~part of~~OF ~~these~~CASH ~~condensed~~FLOWS ~~consolidated~~FOR ~~financial~~THE ~~statements.~~SIX MONTHS ENDED MARCH 31, 2022 AND 2021 (Unaudited)

	2022			2021
Cash flows from operating activities:
Net loss	$	(113,918	)	$	(50,066	)
Adjustment to reconcile net loss to net cash used in operating activities:
Gain on forgiveness of debt		(1,539	)		(3,029	)
Change in operating assets and liabilities:
Prepaids		(4,125	)		-
Accounts payable		(8,904	)		13,967
Accounts payable - related parties		(312	)		34,356
Accrued liabilities		73,727			4,712
Net cash used in operating activities		(55,071	)		(60	)

Cash flows from financing activities:
Payments on notes payable		(10,000	)		-
Payment on convertible note payable		(20,000	)		-
Net cash used in financing activities		(30,000	)		-

Net change in cash		(85,071	)		(60	)
Cash, beginning of period		261,152			408
Cash, end of period	$	176,081		$	348

Supplemental disclosure of cash flow information
Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

~~PEAK~~The accompanying ~~PHARMACEUTICALS,~~footnotes ~~INC~~are an integral part of these unaudited condensed consolidated financial statements.

~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS~~6

~~FOR THE NINE MONTHS ENDED JUNE 30~~PEAK PHARMACEUTICALS, ~~2018 AND 2017~~INC.

~~(Unaudited)~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	For the Nine Months Ended
	June 30,
	2018		2017
Cash flows from operating activities:
Net loss	$	(21,302)	$	(26,984)
Adjustment to reconcile net loss to net cash used in operating activities:
Change in fair value of convertible debt		-		5,000
Change in operating assets and liabilities:
Prepaids		-		(6,000)
Deposits		-		-
Accounts payable		(13,456)		36,984
Disposal of discontinued operations		-		(27,000)
Accrued liabilities		6,126		-
Net cash used in operating activities		(28,632)		(18,000)
Cash flows from financing activities:
Proceeds from issuance of notes payable		43,000		20,000
Net cash provided by financing activities		43,000		20,000
Net change in cash		14,368		2,000
Cash, beginning of period		2,991		1,304
Cash, end of period	$	17,359	$	3,303
Supplemental disclosure of cash flow information
Cash paid for interest	$	-	$	-
Cash paid for income taxes	$	-	$	-

(Unaudited)

~~See~~NOTE 1 ~~the~~– ~~accompanying notes~~NATURE toOF ~~the~~OPERATIONS, ~~condensed~~BASIS ~~consolidated~~OF ~~financial~~PRESENTATION ~~statements~~ AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company ~~accompanying~~was ~~footnotes~~incorporated ~~are~~in anNevada ~~integral~~on ~~part~~December 18, 2007. After a number of name changes, we again, changed our name to Peak Pharmaceuticals, Inc. on December 23, 2014. This name was consistent with our business operations and plans relating to development, manufacturing and marketing of ~~these~~hemp-based ~~condensed~~nutraceutical ~~consolidated~~and ~~financial~~supplement ~~statements~~products for the human and animal health markets. On October 1, 2015, we discontinued certain operations of the Company.

5The Company is currently a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act).

~~PEAK~~Throughout this ~~PHARMACEUTICALS~~report, ~~INC~~the terms “our,” “we,” “us,” and the “Company” refer to Peak Pharmaceuticals, Inc. and its wholly-owned subsidiary, Peak BioPharma Corp.

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL~~Basis ~~STATEMENTS~~of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (~~Unaudited~~“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2021. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period.

~~NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND~~Basis ~~SUMMARY~~of ~~OF SIGNIFICANT ACCOUNTING POLICIES~~Consolidation

The ~~Company was incorporated~~ inunaudited ~~Nevada~~condensed onconsolidated ~~December~~financial ~~18,~~statements ~~2007.~~include ~~After~~the afinancial ~~number~~statements of ~~name~~the ~~changes,~~Company weand ~~again, changed~~ our ~~name~~wholly toowned subsidiary Peak ~~Pharmaceuticals,~~BioPharma ~~Inc~~Corp. onAll ~~December 23, 2014. This name was consistent with our business operations and plans relating to development, manufacturing and marketing of hemp~~inter-~~based~~company ~~nutraceutical~~balances and ~~supplement~~transactions ~~products~~among ~~for~~ the ~~human~~companies ~~and~~have ~~animal~~been ~~health~~eliminated ~~markets.~~upon ~~On October 1, 2015, we discontinued certain operations of the Company~~consolidation.

~~Throughout this report,~~Use ~~the~~of ~~terms “our,” “we,” “us,” and the “Company” refer to Peak Pharmaceuticals, Inc. and its subsidiary, Peak BioPharma Corp.~~Estimates

~~Basis~~The preparation of ~~Presentation~~unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

~~The accompanying unaudited~~Significant ~~condensed~~estimates ~~consolidated~~made ~~financial statements of the Company have been prepared~~ in ~~accordance~~connection with ~~generally~~the ~~accepted~~accompanying accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statements ~~should~~include ~~be read in conjunction with~~ the ~~financial~~valuation ~~statements~~allowances ~~and~~against ~~notes thereto~~net ~~included in our annual report on Form 10-K for the year ended September 30, 2017. In management's opinion, all adjustments~~deferred ~~(consisting~~tax ~~only~~assets ofand ~~normal~~accounting ~~recurring adjustments) considered necessary~~ for aconvertible ~~fair presentation to make our financial statements not misleading have been included~~debt. ~~The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period.~~

~~Recent~~Loss Per ~~Pronouncements~~Share

~~From~~We calculate ~~time~~net toloss ~~time~~per share in accordance with ASC Topic 260, ~~new~~Earnings per Share. Basic net loss per share is computed by dividing ~~accounting~~net ~~pronouncements~~loss ~~are~~by ~~issued~~the ~~that~~weighted weaverage ~~adopt~~number asof shares of common stock outstanding for the ~~specified~~period, ~~effective~~and ~~date.~~diluted Weearnings ~~believe~~per ~~that~~share is computed by including common stock equivalents outstanding for the ~~impact~~period ofin ~~recently~~the ~~issued standards~~denominator. ~~that~~For ~~are~~the ~~not~~three ~~yet~~and ~~effective~~six ~~may~~months ended March 31, 2022 and 2021, any equivalents would have anbeen ~~impact~~anti-dilutive onas ~~our~~we ~~results~~had ofnet ~~operations~~losses ~~and~~for ~~financial~~the ~~position~~periods then ended.

In February 2016, the FASB issued ASU No. 2016-02, Leases, to improve financial reporting about leasing transactions. This ASU will require organizations that lease assets (“lessees”) to recognize a lease liability and a right-of-use asset on its balance sheet for all leases with terms of more than twelve months. A lease liability is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis and a right-of-use asset represents the lessee’s right to use, or control use of, a specified asset for the lease term. The amendments in this ASU simplify the accounting for sale and leaseback transactions primarily because lessees must recognize lease assets and lease liabilities. This ASU leaves the accounting for the organizations that own the assets leased to the lessee (“lessor”) largely unchanged except for targeted improvements to align it with the lessee accounting model and Topic 606, Revenue from Contracts with Customers. ASU No. 2016-02 is effective for reporting periods beginning after December 15, 2018. We do not expect the adoption of this guidance to have an impact on our consolidated financial statements.7

InAs of ~~April~~September ~~2016~~30, 2021, the ~~FASB issued~~Company ~~ASU~~had ~~2016~~two convertible –notes 10with ~~“Revenue~~principal ~~from~~and ~~Contract~~accrued ~~with~~interest ~~Customers:~~balances ~~identifying~~totaling ~~Performance Obligations~~ and ~~Licensing”~~$32,366. ~~The~~During ~~amendments~~the insix ~~this~~months ~~Update~~ended ~~clarify~~December 31, 2021, the ~~two~~Company ~~following~~repaid ~~aspects~~one ~~(a)~~of ~~contracts~~these ~~with~~notes ~~customers~~and torelated ~~transfer~~accrued ~~goods~~interest ~~and~~totaling ~~services~~$15,408. inAs ~~exchange~~of ~~for~~March ~~consideration~~31, ~~and~~2022, ~~(b)~~the ~~determining~~Company ~~whether~~had anone ~~entity’s~~convertible ~~promise~~note toremaining ~~grant~~with aprincipal ~~license~~and ~~provides~~accrued ainterest ~~customer~~totaling ~~with either~~$17,948. The anote ~~right~~holders are entitled, at their option, to ~~use~~convert ~~the~~all ~~entity’s~~or ~~intellectual~~a ~~property~~part ~~(which~~of istheir ~~satisfied~~options at athe ~~point~~date ininto ~~time)~~shares orof athe ~~right~~of tocommon ~~access~~stock in the ~~entity’s intellectual~~Company ~~property~~at ~~(which~~a isprice ~~satisfied~~equal ~~over~~to ~~time).~~a ~~The~~20% ~~amendments~~discount into ~~this~~the ~~Update~~closing ~~are~~price ~~intended~~of tothe ~~reduce~~common stock on the ~~degree~~date of ~~judgement~~the lender’s notice of ~~necessary~~conversion, subject to ~~comply~~a ~~with~~floor ~~Topic~~of ~~606~~$0.01. ~~This~~These ~~guidance~~common ~~has~~stock noequivalents ~~effective~~of ~~date~~approximately 282,198 and 275,551 shares as ~~yet.~~of ~~The~~March ~~Company~~31, is2022 and ~~currently~~2021, ~~evaluating~~respectively, are not included in the ~~impact~~ calculation of ~~adopting~~diluted ~~this~~EPS ~~guidance~~as their effect would be anti-dilutive.

6As of March 31, 2022 and September 30, 2021, the Company had 3,291,000 in stock options outstanding which are exercisable at the holders’ option, with an exercise price of $0.0067, which are not included in the calculation of diluted EPS as their effect would be anti-dilutive.

~~In August 2016, the FASB~~Recently ~~issued~~Issued ~~ASU~~Accounting 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for the Company beginning in the first quarter of fiscal 2019. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the impact of adopting this guidance.Pronouncements

~~In November 2016, the FASB~~Management ~~issued~~does ~~ASU~~not ~~2016-18,~~believe ~~“Statement of Cash Flows (Topic 230) Restricted Cash”. The new guidance requires~~ that ~~the~~any ~~reconciliation of~~recently the beginning-of-period and end-of-period amounts shown in the statement of cash flows include restricted cash and restricted cash equivalents. If restricted cash is presented separately from cash and cash equivalents on the balance sheetissued, ~~companies~~but ~~will be~~not ~~required~~yet to reconcile the amounts presented on the statement of cash flows to the amounts on the balance sheet. Companies will also need to disclose information about the nature of the restrictions. The guidance is effective, ~~for~~accounting ~~fiscal~~pronouncements, ~~years~~if ~~beginning~~currently ~~after December 15~~adopted, ~~2017,~~would ~~and~~have ~~interim~~a ~~periods within those fiscal years. The Company has determined that the adoption of this guidance~~material ~~has~~effect ~~no impact~~ on ~~its~~the ~~consolidated~~Company’s financial statements.

InFrom time ~~January~~to ~~2017~~time, ~~FASB~~new ~~issued ASU~~accounting ~~2017-01,~~pronouncements ~~“Business~~are ~~Combinations~~issued ~~(Topic~~that ~~805)~~we ~~Clarifying~~adopt ~~the~~as ~~Definition~~ of athe ~~Business”.~~specified ~~The~~effective ~~amendments~~date. inWe ~~this~~believe ~~Update is~~that ~~to clarify~~ the ~~definition~~impact of ~~a business with the objective of adding guidance to assist entities with evaluating whether transactions~~ ~~should~~recently beissued ~~accounted~~standards ~~for~~that asare ~~acquisitions~~not ~~(or~~yet ~~disposals)~~effective ofmay ~~assets~~have oran ~~businesses.~~impact ~~The~~on ~~definition~~our ofresults ~~a business affects many areas~~ of ~~accounting~~operations ~~including acquisitions, disposals, goodwill,~~ and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company has determined that the adoption of this guidance has no impact on its consolidated financial ~~statements~~position.

On August ~~May 10~~5, ~~2017~~2020, the ~~Financial Accounting Standards Board (“~~FASB”) issued an Accounting Standards Update (“ASU”) ~~2017~~2020-0906, ~~“Compensation~~Debt—~~Stock Compensation~~Debt ~~(Topic~~with ~~718):~~Conversion ~~Scope~~and ofOther ~~Modification~~Options ~~Accounting”,~~(Subtopic 470-20) ~~which~~and ~~provides~~Derivatives ~~guidance~~and toHedging—Contracts ~~clarify~~in ~~when~~Entity’s toOwn ~~account~~Equity ~~for~~(Subtopic a815-40, ~~change to~~which simplifies the ~~terms~~accounting for orcertain ~~conditions~~financial instruments with characteristics of aliabilities ~~share-based~~and ~~payment~~equity, ~~award~~including asconvertible ainstruments ~~modification~~and contracts on an entity’s own equity. ~~Under~~The ~~the~~ASU’s ~~new~~amendments ~~guidance,~~are ~~modification~~effective ~~accounting~~for ispublic business entities that are not smaller reporting companies ~~required~~for ~~only~~fiscal ifyears ~~the~~beginning ~~fair~~after ~~value~~December 15, ~~the~~2021, ~~vesting~~and ~~conditions,~~interim orperiods ~~the~~within ~~classification~~those offiscal years. For all other entities, the ~~award~~amendments are ~~(as~~effective ~~equity~~for orfiscal ~~liability)~~years ~~changes~~beginning ~~as a~~after ~~result~~December of15, ~~the~~2023, ~~change~~and ininterim ~~terms~~periods orwithin ~~conditions~~those fiscal years. The guidance ismay ~~effective~~be early ~~prospectively~~adopted for ~~all~~fiscal ~~companies~~years ~~for annual periods~~ beginning on or after December 15, ~~2017.~~2020, ~~Early~~and ~~adoption~~interim isperiods ~~permitted~~within those fiscal years. The Company has determined that the adoption of this guidance has no impact on its consolidated financial statements.

~~NOTE~~In June 22016, –the ~~GOING~~FASB ~~CONCERN~~issued ~~AND~~ASU ~~MANAGEMENT’S~~No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial ~~LIQUIDITY~~Instruments ~~PLANS~~(“ASU 2016-13”). ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842). ASU 2019-10 changes the effective date of the credit loss standard (ASU 2016-13) to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years for smaller reporting companies. Further, the ASU clarifies that operating lease receivables are not within the scope of ASC 326-20 and should instead be accounted for under the new leasing standard, ASC 842. The Company has determined that the adoption of this guidance has no impact on its consolidated financial statements.

~~As of June 30, 2018, the~~Recently ~~Company~~Adopted ~~had~~Accounting an accumulated deficit of $5,077,511 and a working capital deficiency of $214,110. During the nine months ended June 30, 2018, the Company used cash in operating activities of $28,632. As of June 30, 2018, the Company had cash of $17,359. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company recognizes it will need to raise additional capital in order to fund operations and meet its payment obligations. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will generate revenues, become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms, it will have to develop and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.Pronouncements

~~Accordingly~~In December 2019, the ~~accompanying consolidated~~FASB ~~financial~~issued ~~statements~~ASU ~~have~~No. ~~been~~2019-12, ~~prepared~~Income inTaxes ~~conformity~~– ~~with~~Simplifying ~~U.S.~~the ~~GAAP~~Accounting for Income Taxes (Topic 740), (“ASU 2019-12”), which ~~contemplates~~simplifies ~~continuation~~income oftax ~~the~~accounting ~~Company as~~in avarious ~~going~~areas ~~concern~~including, ~~and~~but not limited to, the ~~realization~~accounting offor hybrid ~~assets~~tax ~~and~~regimes, ~~the~~tax ~~satisfaction~~implications ofrelated ~~liabilities~~to inbusiness ~~the~~combinations, ~~normal~~and ~~course~~interim ofperiod ~~business.~~accounting ~~The~~for ~~carrying~~enacted changes in tax law, ~~amounts~~along ofwith ~~assets~~some ~~and~~codification ~~liabilities~~improvements. ~~presented~~ASU in2019-12 ~~the~~is ~~consolidated~~effective ~~financial~~for ~~statements~~interim doand ~~not~~annual ~~necessarily~~periods ~~represent~~beginning ~~realizable~~after ~~or settlement~~December ~~values.~~15, 2020. The ~~consolidated~~Company ~~financial~~adopted ~~statements~~ASU do2019-12 ~~not~~on ~~include~~September ~~any~~30, ~~adjustments~~2021 ~~that~~and ~~might~~has ~~result~~determined ~~from~~that the ~~outcome~~adoption of this guidance had no impact on its consolidated ~~uncertainty~~financial statements.

7In August 2018, the FASB issued ASU No. 2018-13, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The guidance is effective for all entities for fiscal years beginning after December 15, 2019, including interim periods therein. Early adoption is permitted for any eliminated or modified disclosures upon issuance of ASU 2018-13. The Company adopted ASU 2018-13 on October 1, 2020 and has determined that the adoption of this guidance had no impact on its consolidated financial statements.

~~NOTE 3 – RELATED PARTY TRANSACTIONS~~8

~~Parties, which can be corporations~~NOTE or2 ~~individuals,~~– ~~are~~GOING ~~considered~~CONCERN toAND beMANAGEMENT’S ~~related~~LIQUIDITY if they have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence.PLANS

~~Accounts payable –~~As ~~related~~of ~~parties~~March ~~are~~31, 2022, the ~~amounts~~Company ~~payable~~had toan ~~officers~~accumulated deficit of $5,303,505 and ~~directors~~a working capital deficiency of $440,103. During the six months ended March 31, 2022, the Company ~~for~~incurred ~~reimbursement~~a net loss of ~~expenses~~$113,918 and ~~they~~used ~~incurred~~cash onin operating activities of $55,071. ~~behalf~~As of March 31, 2022, the Company ashad ~~well~~cash asof ~~Directors~~$176,081. These conditions raise substantial doubt about the Company’s ~~fees~~ability ~~and~~to continue ~~salaries~~as a going concern. ~~Included~~The Company recognizes it will need to raise additional capital in ~~accounts~~order ~~payable~~to atfund ~~June~~operations ~~30,~~and ~~2018~~meet ~~are~~its payment ~~amounts~~obligations. There is no assurance that additional financing will be available when needed or that management will be able to ~~totaling~~obtain ~~$47,877~~financing ~~(December~~on 31terms acceptable to the Company and whether the Company will generate revenues, ~~2017~~become ~~$47~~profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds on favorable terms,~~877)~~ ~~owed~~it will have to ~~related~~develop ~~parties~~and implement a plan to further extend payables and to raise capital through the issuance of debt or equity on less favorable terms until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

~~NOTE~~Accordingly, the 4accompanying ~~–NOTES~~unaudited ~~PAYABLE~~condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~Loan~~NOTE 3 ~~with~~– ~~Trius~~RELATED ~~Holdings~~PARTY ~~Limited~~TRANSACTIONS

~~On March 17~~Parties, ~~2017, the~~ ~~Company~~which ~~entered~~can ~~into~~be ancorporations ~~agreement~~or ~~with~~individuals, ~~Trius~~are ~~Holdings~~considered ~~Limited~~to ~~(“Trius”).~~be ~~Pursuant~~related toif ~~the~~they ~~terms~~have of the ~~agreement~~ability, ~~Trius acquired~~directly aor ~~12% convertible note with an aggregate face value of $10~~indirectly,~~000.~~ ~~The~~to ~~note~~control ~~matures in one year. Trius is entitled, at its~~the ~~option,~~other toparty ~~convert all~~ or aexercise ~~part~~significant ofinfluence ~~the~~over ~~principal outstanding at~~ the ~~date~~other ~~into~~party ~~shares~~in ofmaking ~~the~~financial ofand ~~common~~operating ~~stock~~decisions. inCompanies ~~the~~are ~~Company~~also atconsidered ~~a price equal~~ to abe ~~20%~~related ~~discount~~if tothey ~~the~~are ~~closing price of the common stock on the date of the lender’s notice of conversion,~~ subject to acommon ~~floor~~control ofor ~~$0.01.~~common Onsignificant ~~May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 21, 2018 to March 21, 2019~~influence.

~~Loan~~Accounts payable – related parties are amounts payable to current and former officers and directors for services provided to the Company totaling $133,674 and $133,986, as of March 31, 2022 and September 30, 2021, respectively. These amounts include accounts payable to an entity controlled by our sole officer and director for financial services such entity is incurring on behalf of the Company totaling $58,797 and $59,109 as of March 31, 2022 and September 30, 2021, respectively. Total expense incurred related to this entity was $3,279 and $22,848, and $8,049 and $27,578, for the three and six months ended March 31, 2022 and 2021, respectively, with ~~Individual~~no other related party expenses incurred.

~~On March 30, 2017, the~~NOTE ~~Company~~4 ~~entered~~– ~~into~~CONVERTIBLE anNOTES ~~agreement~~PAYABLE ~~with~~AND anNOTES individual. Pursuant to the terms of the agreement, the individual acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year. The individual is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 30, 2018 to March 30, 2019.PAYABLE

~~Loan~~Convertible Notes ~~with Mediapark Investments Limited~~Payable

~~On January 10, 2018, the~~Loan ~~Company entered into an agreement~~ with ~~Mediapark~~Trius ~~Investments~~Holdings Limited (“Mediapark”.) Pursuant to the terms of the agreement, Mediapark acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days on July 10, 2018. As of July 9, 2018, the loan was extended to July 10, 2019.

~~Loan~~On March 17, 2017, the Company entered into an agreement with ~~Individual~~Trius Holdings Limited (“Trius”). Pursuant to the terms of the agreement, Trius acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. Trius is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 21, 2018 to March 21, 2019. As of March 31, 2022 and September 30, 2021, the total accrued interest owing under this note was $6,937 and $6,205, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%.

On April 2, 2018, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, we received a promissory note in the amount of $20,000. The note is due and payable in full on October 2, 2018 and it accrues interest at a rate of 12% per annum.9

~~Total accrued interest~~Loan onwith ~~the above notes was $4,336 as of June 30, 2018 (March 31, 2018 $3,049) and is reflected in accrued liabilities on the accompanying balance sheet.~~Individual

~~NOTE~~On March 530, –2017, ~~STOCKHOLDERS~~the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, the individual acquired a 12% convertible note with an aggregate face value of $10,000. The note matures in one year and is unsecured. The individual is entitled, at its option, to convert all or a part of the principal outstanding at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s ~~EQUITY~~notice of conversion, subject to a floor of $0.01. The default interest rate is 15%. On May 11, 2018, the agreement had been amended to extend the maturing date of the note from March 30, 2018 to March 30, 2019. As of March 31, 2022 and September 30, 2021, the total accrued interest owing under this note was $0 and $6,160, respectively. On December 3, 2021, the Company repaid this loan and accrued interest in full.

~~We had no preferred or~~Notes ~~common stock transactions during the nine-month period ended June 30, 2018 and 2017.~~Payable

8 Loan with Mediapark Investments Limited

~~NOTE~~On January 610, –2018, ~~OPTIONS~~the Company entered into an agreement with Mediapark Investments Limited (“Mediapark”.) Pursuant to the terms of the agreement, Mediapark acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days on July 10, 2018 and is unsecured. As of July 9, 2018, the loan was extended to July 10, 2019. As of March 31, 2022 and September 30, 2021, the total accrued interest owing under this note was $13,552 and $11,813, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 15%.

~~No stock options were granted~~Loan ~~during~~with ~~the quarters ended June 30, 2018 and 2017.~~Individual

~~The~~On April ~~following~~2, is2018, the Company entered into an agreement with an individual. Pursuant to the terms of the agreement, we received a ~~summary~~promissory note in the amount of ~~outstanding~~$20,000. ~~stock~~The ~~options~~note ~~issued~~is tounsecured, ~~employees~~is due and ~~directors~~payable asin full on October 2, 2018, and it accrues interest at a rate of ~~June~~12% per annum. As of March 31, 2022 and September 30, ~~2018:~~2021, the total accrued interest owing under this note was $0 and $9,883, respectively. On December 3, 2021, the Company repaid this loan and accrued interest in full.

	Number of Options	Exercise Price per Share		Average Remaining Term in Years
Outstanding September 30, 2017 and June 30, 2018	2,916,000		$0.0067	5.70
Exercisable	2,916,000		$0.0067	5.70

Loan with Officer

On June 14, 2021, the Company entered into an agreement with our sole officer and director. Pursuant to the terms of the agreement, we received a promissory note in the amount of $5,000. The ~~following~~note is aunsecured, ~~summary~~is due and payable in full on December 31, 2021, and accrues interest at a rate of ~~outstanding~~1.5% ~~stock~~per ~~options~~annum. ~~issued~~As toof ~~non-employees~~March 31, ~~excluding~~2022 ~~directors~~and September 30, as2021, the total accrued interest owing under this note was $164 and $41, respectively. As of ~~June~~the 30date of this report, ~~2018:~~the due date has not been extended and the note is in default.

	Number of Options	Exercise Price per Share		Average Remaining Term in Years
Outstanding September 30, 2017 and June 30, 2018	375,000		$0.0067	5.30
Exercisable	375,000		$0.0067	5.30

During the three months ended September 30, 2021, the Company entered into a note payable with our sole officer and director for $30,000. The note is unsecured, is due and payable in full on December 31, 2021 and accrues interest at a rate of 1.5% per annum. As of March 31, 2022 and September 30, 2021, the total accrued interest owing under this note was $856 and $2, respectively. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 10%.

~~There was no equity-based~~Notes ~~compensation~~Payable ~~for~~Issued During the ~~nine~~Twelve ~~months~~Months ~~ended~~Ended ~~June~~September 30, ~~2018 and 2017.~~ 2021

9During the twelve months ended September 30, 2021, the Company entered into twelve notes payable totaling $240,000. The notes are unsecured, are due and payable in full on September 30, 2021, and accrue interest at a rate of 1.5% per annum. As of March 31, 2022 and September 30, 2021, the total accrued interest owing under these notes was $12,713 and $755. In June 2022, the Company repaid one of the notes with a principal balance of $35,000. As of the date of this report, that date has not been extended, and the Company is accruing interest at the default interest rate of 10%.

~~Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations~~10

~~Forward-Looking~~NOTE 5 ~~Statements~~– OPTIONS

~~This report contains forward-looking~~No ~~statements.~~stock ~~The~~options ~~following~~were ~~discussion~~granted ~~should~~during ~~be read in conjunction with~~ the ~~financial~~six ~~statements~~months ~~and~~ended ~~related~~March ~~notes contained in our Annual Report on Form 10-K~~31, as2022 ~~filed~~and ~~with the Securities & Exchange Commission on January 12, 2018~~2021. Certain statements made in this discussion are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements are projections in respect of future events or financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology.

~~These statements are only~~The ~~predictions~~following ~~and~~is ~~involve~~a ~~known~~summary and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” set forth in our Annual Report on Form 10-K for the year ended September 30, 2017, as filed on January 12, 2018, any of ~~which~~outstanding ~~may~~stock ~~cause~~options ~~our~~issued ~~company’s or our industry’s actual results, levels of activity, performance or achievements~~ to beemployees ~~materially~~and ~~different~~directors ~~from~~as ~~any future results, levels~~ of ~~activity,~~March ~~performance or achievements expressed or implied by these forward-looking statements. These risks may cause the Company’s or its industry’s actual results~~31, ~~levels~~2022 ofand ~~activity or~~September ~~performance to be materially different from any future results~~30, ~~levels of activity or performance expressed or implied by these forward-looking statements.~~2021:

~~Although~~Schedule ~~the~~of ~~Company believes that the expectations reflected in the forward~~share-~~looking~~based ~~statements are reasonable~~compensation, itstock ~~cannot guarantee future results~~options, ~~levels of~~ activity or performance. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. The Company is under no duty to update any forward-looking statements after the date of this report to conform these statements to actual results.

As used in this quarterly report and unless otherwise indicated, the terms “we,” “us,” “our,” “Peak,” or the “Company” refer to Peak Pharmaceuticals, Inc, including our wholly-owned subsidiary Peak BioPharma Corp (“Peak BioPharma”). Unless otherwise specified, all dollar amounts are expressed in United States dollars.

	Number of Options		Exercise Price per Share		Average Remaining Term in Years
Outstanding March 31, 2022 and September 30, 2021		2,916,000	$	0.0067		1.95
Exercisable, March 31, 2022 and September 30, 2021		2,916,000	$	0.0067		1.95

~~Corporate~~The ~~Overview~~following is a summary of outstanding stock options issued to non-employees, excluding directors, as of March 31, 2022 and September 30, 2021:

WeSchedule ~~were~~of ~~incorporated~~share-based ~~as Surf A Movie Solutions Inc. in Nevada on December 18~~compensation, ~~2007~~stock ~~to engage in the business of the development~~options, ~~sales and marketing of online video stores. We were not successful in our efforts and have ceased this line of business.~~activity

On October 10, 2013, we entered into a joint venture agreement with Produced Water Solutions, Inc., a Colorado corporation, that was in the business of providing economically and environmentally sound solutions for the treatment and recycling of wastewater resulting principally from oil and gas exploration and production activities. As a result of our research of this business opportunity, on December 31, 2013, we determined not to move forward with this line of business.

	Number of Options		Exercise Price per Share		Average Remaining Term in Years

Outstanding March 31, 2022 and September 30, 2021		375,000	$	0.0067		1.54
Exercisable, March 31, 2022 and September 30, 2021		375,000	$	0.0067		1.54

~~In early March 2014, we~~There ~~entered~~was ~~into~~no ~~the~~equity-based ~~business~~compensation ~~of developing, manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp,~~ for the ~~prevention~~six ~~and~~months ~~alleviation~~ended ~~of various conditions and diseases. In connection therewith, on~~ March 1731, ~~2014~~2022 weand ~~changed our name to Cannabis Therapy Corp~~2021. ~~On December 23, 2014, we changed our name to Peak Pharmaceuticals, Inc. All of our business operations are carried on through our wholly-owned subsidiary, Peak BioPharma Corp., a Colorado corporation.~~

On July 29, 2014, through Peak BioPharma, we entered into a license agreement (the “License Agreement”) with Canna-Pet, LLC (“Licensor”), a Washington limited liability company, which owns the brand name “Canna-Pet” and certain related intellectual property including, but not limited to, trademarks and copyrights, formulations, recipes, production processes and systems, websites, domain names, customer lists, supplier lists, trade secrets and know-how, and other related intellectual property (collectively, the “Licensed Intellectual Property”), used by Licensor in the conduct of its business related to the production and sale of medical products made from industrial hemp which are intended exclusively for consumption by pets. Pursuant to the License Agreement, the Licensor granted to us a perpetual, exclusive, world-wide license to use the Licensed Intellectual Property in conjunction with our business and the production and sale of medical products made from industrial hemp as well as the right to sublicense the Licensed Intellectual Property to third parties. The License Agreement gives us the right to produce and sell existing products utilizing the Licensed Intellectual Property and to develop new products, jointly with Licensor or otherwise, based upon the Licensed Intellectual Property. The License Agreement provided us with an immediate revenue source and access to Licensor’s customer base. During the term of the license, all intellectual property rights in and to the Licensed Intellectual Property remained the exclusive property of Licensor.11

10 ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

In consideration of the grant of the license, we agreed to pay Licensor license fees in the form of royalty payments calculated on the basis of gross proceeds received by us from sales of products manufactured, marketed or sold by us utilizing the Licensed Intellectual Property or any subsequently developed intellectual property which is jointly owned by us and Licensor. We began selling CannaForward-~~Pet products in~~Looking ~~October 2014.~~Statements

~~Based~~This report ~~upon~~contains ~~recent~~forward-looking ~~regulatory activity~~statements. ~~related~~The tofollowing ~~imposition~~discussion ofshould ~~restrictions~~be read in conjunction with the financial statements and related ~~limitations~~notes contained in our Annual Report on Form 10-K, as filed with the ~~sale~~Securities of& ~~hemp-based~~Exchange ~~health~~Commission ~~products~~on ~~for~~December ~~pets~~19, we2022. Certain ~~elected~~statements ~~to terminate~~made ~~our~~in ~~license~~this ~~agreement~~discussion ~~with~~are “forward-looking statements” within the ~~Licensor,~~meaning ~~effective~~of asThe Private Securities Litigation Reform Act of ~~October~~1995. 1Forward-looking statements are projections in respect of future events or financial performance. In some cases, ~~2015~~you can identify forward-looking statements by terminology such as “may,” ~~and~~“should,” to“expects,” ~~cease~~“plans,” “anticipates,” ~~all~~“believes,” ~~operations~~“estimates,” ~~relating~~“predicts,” to“potential” ~~sale~~or “continue” or the negative of ~~hemp-based~~these ~~products~~terms ~~for~~or ~~pets~~other comparable terminology.

OnThese statements ~~October~~are 12only predictions and involve known and unknown risks, ~~2015~~uncertainties and other factors, weincluding the risks in the section ~~entered~~entitled ~~into~~“Risk anFactors” ~~agreement~~set forth in our Annual Report on Form 10-K for the ~~termination~~year ~~(“Termination~~ended ~~Agreement”)~~September 30, 2021, as filed on December 19, 2022, any of ~~the~~which ~~License~~may ~~Agreement~~cause our company’s or our industry’s actual results, ~~effectively~~levels ~~selling~~of activity, performance or achievements ~~the~~to ~~discontinued~~be ~~operations~~materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. ~~The~~These ~~Termination~~risks ~~Agreement~~may ~~contained~~cause the ~~following~~Company’s ~~provisions:~~or its industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.

·Although the ~~Termination~~Company ofbelieves ~~License:~~that ~~The~~the ~~parties~~expectations ~~agreed~~reflected toin ~~terminate~~ the ~~License~~forward-looking ~~Agreement~~statements ~~effective~~are asreasonable, ofit ~~October~~cannot 1guarantee future results, levels ~~2015~~of activity or performance. Moreover, ~~this~~neither ~~termination~~the ~~was~~Company ~~made~~nor byany ~~mutual~~other ~~agreement~~person ofassumes responsibility for the ~~parties~~accuracy ~~pursuant~~and completeness of these forward-looking statements. The Company is under no duty to ~~and~~update inany ~~accordance~~forward-looking ~~with~~statements after the ~~provisions~~date of ~~the~~this ~~License~~report to ~~Agreement~~conform these statements to actual results.

·As used ~~Return~~in ofthis ~~Licensed~~quarterly ~~Intellectual~~report ~~Property: We agreed to return all Licensed Intellectual Property to the Licensor,~~ and ~~our~~unless ~~right~~otherwise ~~to use all~~indicated, orthe ~~any~~terms ~~portion~~“we,” ~~of the Licensed Intellectual Property ceased effective as of October 1~~“us,” ~~2015~~“our,” ~~Pursuant to the terms of the License Agreement~~“Peak,” or the ~~Licensed Intellectual Property included the brand name~~ “~~Canna-Pet~~Company” ~~and~~refer ~~certain~~to ~~related~~Peak ~~intellectual~~Pharmaceuticals, ~~property~~Inc, including, ~~but~~our ~~not~~wholly-owned ~~limited,~~subsidiary ~~trademarks~~Peak ~~and~~BioPharma ~~copyrights,~~Corp ~~formulations,~~(“Peak BioPharma”). ~~recipes,~~Unless ~~production~~otherwise ~~processes and systems~~specified, ~~websites,~~all ~~domain~~dollar ~~names,~~amounts ~~customer~~are ~~lists,~~expressed ~~supplier~~in ~~lists~~United ~~trade~~States ~~secrets and know- how, and other related intellectual property~~dollars.

·Corporate History ~~Return of Other Property: In addition to return of the Licensed Intellectual Property, we agreed to transfer to Licensor all product inventory, Colorado hemp with permits~~ and authorization, all production/fulfillment contracts, all e-commerce accounts and processing, all non-disclosure and research agreements and any and all other property in our possession which was used by us in the conduct of our business related to production and sale of medical cannabis products for pets made from hemp and low-THC cannabis plants.Overview

·We were ~~Office~~first ~~Space~~incorporated in Nevada as Surf A Movie Solutions, ~~Equipment~~Inc. ~~and~~on ~~Employees:~~December In18, ~~conjunction~~2007 ~~with~~to engage in the ~~execution~~business of the ~~Termination~~development ~~Agreement,~~sale and wemarketing ~~granted~~of ~~the~~online ~~Licensor~~video ~~the~~sales. ~~right~~We towere ~~use~~not successful in our ~~office~~efforts ~~space,~~and ~~for~~discontinued ~~the~~this ~~three-month~~line ~~period~~of ~~from~~business. ~~October~~Since 1,that ~~2015~~time ~~through~~and until ~~December~~August 318, ~~2015~~2014, onwe were a ~~rent~~“shell company” (as such term is defined in Rule 12b-~~free~~2 ~~basis~~under the Exchange Act).

·On August ~~Consideration:~~30, As2013, ~~consideration~~we ~~for~~changed ~~the~~our ~~cancellation~~name ofto ~~the~~Frac ~~License~~Water ~~Agreement~~Systems, Inc. and, ~~the~~on ~~return~~October ~~of other property~~10, ~~as described above~~2013, ~~the~~we ~~Licensor~~decided ~~agreed~~ to ~~waive~~engage ~~payment~~in bythe usbusiness ~~and~~of toproviding economically ~~release~~and usenvironmentally ~~from~~sound ~~liability~~solutions for ~~payment~~the oftreatment ~~any~~ and ~~all~~recycling ~~unpaid~~of ~~royalties,~~wastewater ~~invoices~~resulting ~~and~~principally ~~other~~from ~~amounts~~oil ~~which~~and ~~were~~gas exploration ~~otherwise~~and ~~currently~~production ~~due~~activities. ~~and~~Due ~~payable~~to byour usresearch toof ~~Licensor~~the ~~for~~business ~~sales~~opportunities, ofon ~~Canna-Pet~~December ~~products~~31, ~~for~~2013, ~~all~~we ~~periods~~determined ~~through~~not ~~and~~to move ~~including~~forward ~~September~~with ~~30,~~this ~~2015~~line of business.

·In early ~~Collections:~~March ~~On October 15~~2014, ~~2015,~~ we ~~forwarded~~decided to enter into the ~~Licensor~~business ~~all~~of ~~payments~~developing, ~~received~~manufacturing byand usmarketing ~~after~~pharmaceutical ~~September~~level 30products containing phytocannabinnoids, ~~2015~~an ~~(net~~abundant ofand ~~amounts~~pharmaceutically ~~received~~active bycomponent usof ~~for~~industrial ~~taxes~~hemp, ~~duties,~~for ~~governmental~~the ~~charges~~prevention and alleviation of various conditions and diseases. In connection therewith, ~~freight~~on orMarch ~~shipping~~17, ~~charges~~2014, we changed our name to Cannabis Therapy Corporation and, ~~the~~on ~~like)~~March 24, ~~for~~2014, ~~Canna-~~changed ~~Pet~~our ~~products~~trading ~~sold~~symbol on orOTC ~~after~~Markets ~~October~~to 1“CTCO”. On December 23, 2014, we changed our name to Peak Pharmaceuticals, Inc. and our trading symbol changed to “PKPH” on February 5, 2015.

11In March 2014 we began operating as a bio-pharmaceutical and nutraceutical company seeking to develop, manufacture, market and sell safe, high quality, medicinal products based on extracts from hemp. Our primary initial focus was on exploitation of the exclusive license we received from Canna-Pet, LLC, a developer of ingestible health products for pets made from hemp. We had also taken initial steps related to development of over-the-counter, THC-free, hemp-based products for the human market for the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases.

~~The following is a summary of the net assets sold as initially determined at Septembers 30, 2015 and updated October 15, 2015:~~12

	October 15, 2015		September 30, 2015
Inventory	$	45,436	$	41,705
Prepaid Expenses		8,821		-
Deposits		8,179		8,678
Total assets	$	62,436	$	50,383
Accounts payable		103,548		124,396
Royalties payable		39,506		39,506
Accrued liabilities		285		15,341
Total liabilities		143,339		179,243
Net assets sold	$	80,903	$	128,860

On July 29, 2014, through our wholly-owned subsidiary, Peak BioPharma Corp., we entered into a License Agreement (the “License Agreement”) with Canna-Pet, LLC, (“Licensor”) a Washington limited liability corporation. They own the brand name “Canna-Pet” and certain related intellectual property including, but not limited to, trademarks and copyrights, formulations, recipes, production processes and systems, websites, domain names, customer lists, supplier lists, trade secrets and know-how, and other related intellectual property (collectively, the “Licensed Intellectual Property”). This is used by the Licensor in the conduct of its business related to the production and sale of medical products made from industrial hemp, which are intended exclusively for consumption by pets. Pursuant to the License Agreement, the Licensor granted to us a perpetual, exclusive, world-wide license to use the Licensed Intellectual Property in conjunction with our business and the production and sale of medical products made from industrial hemp, as well as the right to sublicense the Licensed Intellectual Property to third parties. The License Agreement gave us the right to produce and sell existing products utilizing the Licensed Intellectual Property and to develop new products, jointly with Licensor or otherwise, based upon the Licensed Intellectual Property. The License Agreement provided us with an immediate revenue source and access to Licensor’s customer base. The License Agreement specified that during the term of the license, all intellectual property rights in and to the Licensed Intellectual Property remain the exclusive property of Licensor.

~~Our~~In consideration ~~common~~of ~~stock~~the isgrant ~~currently listed~~of onthe license, we agreed to pay Licensor license fees in the ~~OTC~~form ~~Markets,~~of QBroyalty ~~Tier~~payments calculated based on gross proceeds received by us from sales of products manufactured, ~~under~~marketed or sold by us utilizing the ~~symbol~~Licensed ~~“PKPH”~~Intellectual Property or any subsequently developed intellectual property which is jointly owned by us and Licensor. We began selling Canna-Pet products in October 2014.

~~Recent~~Based upon ~~Corporate~~recent ~~Developments~~regulatory activity related to imposition of restrictions and limitations on the sale of hemp-based health products for pets, we elected to terminate our license agreement with the Licensor, effective as of October 1, 2015, and to cease all operations relating to sale of hemp-based products for pets.

~~Since~~On October 12, 2015, we entered into an agreement for the ~~commencement~~termination (“Termination Agreement”) of the ~~year~~License ~~through~~Agreement, effectively ~~June~~selling 30the discontinued operations. Furthermore, ~~2018~~based on advice from the Food and Drug Administration, as well as our regulatory counsel, we ~~received~~decided ~~two~~to ~~promissory~~revise ~~notes~~our strategy and discontinue all efforts to develop and market hemp-based health products. ~~One~~We ~~promissory~~currently ~~note~~are ~~was~~pursuing to ~~for~~acquire ~~$23,000~~or onmerge ~~January~~with ~~10,~~an ~~2018~~entity ~~and~~with ~~the~~significant ~~other~~operations ~~was~~in order to create a viable business model and value for our shareholders. ~~$20,000~~Since onOctober ~~April~~2015 we have been a “shell company” (as such term is defined in Rule 12b-2, ~~2018~~under the Exchange Act).

~~Loan~~All of ~~Agreements~~our business operations are carried out through our wholly owned subsidiary, Peak BioPharma Corp., a Colorado corporation. Throughout this Report, unless otherwise noted or required by the context, references to “the Company,” “us,” “we,” “our,” and similar terms refer to Peak Pharmaceuticals, Inc. and our wholly owned subsidiary, Peak BioPharma Corp.

~~Loan~~We currently ~~with~~have ~~Trius~~authorized ~~Holdings~~325,000,000 ~~Limited~~shares of capital stock, consisting of (i) 300,000,000 shares of common stock, and (ii) 25,000,000 shares of “blank check” Preferred Stock.

On August ~~March 17~~15, ~~2017~~2012, weour ~~entered into~~board anof ~~agreement~~directors ~~with~~and ~~Trius~~stockholders ~~Holdings~~owning ~~Limited.~~a ~~Pursuant~~majority toof ~~the~~our ~~terms~~outstanding ofcommon ~~the agreement~~shares, ~~the~~authorized ~~investor~~a ~~acquired~~50 afor ~~12%~~1 ~~convertible~~forward ~~note~~stock ~~with~~split anof ~~aggregate~~our ~~face~~issued ~~value~~and ofoutstanding ~~$10,000~~common stock. The ~~note~~forward ~~matures~~split inbecame ~~one~~effective ~~year.~~on ~~The~~September ~~holder~~27, of2012. ~~this~~Due ~~note~~to isthe ~~entitled~~forward split, ateach ~~its~~outstanding ~~option, to~~share ~~convert~~was ~~all~~split orinto a50 ~~part~~shares. ofOn ~~the~~March ~~principal~~11, ~~outstanding~~2014, atour ~~the~~board ~~date~~of ~~into~~directors ~~shares~~authorized ofa ~~the~~1.5 for 1 forward stock split of our common stock in the ~~Company~~form atof a ~~price equal~~dividend. toIn aconnection ~~20%~~therewith, ~~discount~~our toshareholders ~~the~~of ~~closing~~record ~~price~~as of the ~~common~~close ~~stock~~of business on ~~the~~March ~~date~~28, 2014, received an additional 0.5 share of ~~the~~our ~~lender’s~~common ~~notice~~stock for each share of ~~conversion,~~our ~~subject~~issued and outstanding common stock held toby athem ~~floor~~on ofsuch $0date.01 The forward stock split became effective on April 1, 2014.

~~Loan~~Results of ~~with Individual~~Operations

~~On March 30, 2017, we entered~~Comparison ~~into an agreement with an individual. Pursuant to the terms~~ of the ~~agreement,~~Three ~~the~~Months ~~investor~~Ended ~~acquired~~March ~~a 12% convertible note with an aggregate face value of $10~~31,~~000.~~ ~~The~~2022 ~~note matures in one year. The holder of this note is entitled, at its option,~~ to ~~convert all or a part of~~ the ~~principal~~Three ~~outstanding~~Months atEnded ~~the~~March ~~date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion~~31, ~~subject to a floor of $0.01.~~2021

~~Loan with Mediapark Investments Limited~~13

On January 10, 2018, we entered into an agreement with Mediapark Investments Limited. Pursuant to the terms of the agreement, the investor acquired a 12% promissory note with an aggregate face value of $23,000. The note matures in 180 days, on July 10, 2018.Revenue

~~Loan~~No revenue ~~with~~or ~~Individual~~cost of sales were generated for the three months ended March 31, 2022 and 2021.

~~On April 2, 2018, the~~Operating Company entered into an agreement with an individual. Pursuant to the terms of the agreement, we received a promissory note in the amount of $20,000. The note is due and payable in full on October 2, 2018 and it accrues interest at a rate of 12% per annum. Expenses

~~Total~~The Company’s ~~accrued~~expenses ~~interest on~~for the ~~above~~three ~~notes~~months ~~was~~ended ~~$4,336 as of June 30, 2018 (~~March 31, ~~2018~~2022 ~~$3,049)~~ and is2021, ~~reflected~~are insummarized ~~accrued~~as ~~liabilities on the accompanying balance sheet.~~follows:

	Three Months Ended March 31,
	2022		2021
General and administrative (including $3,279 and $22,848 of fees paid to related party)	$	46,561	$	43,243
Total operating expenses	$	46,561	$	43,243

~~Results~~The increase in general and administrative expenses for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 of ~~Operations~~$3,318 is due primarily to an increase in filing fees.

~~Comparison~~Other ofExpenses ~~the Three Months Ended June 30, 2018 to the Three Months Ended June 30, 2017~~

Revenue

	Three Months Ended March 31,
	2022		2021
Interest Expense (including related party interest of $863 and $0)	$	8,002	$	2,498
Gain on forgiveness of debt		-		(3,029	)
Total other expenses	$	8,002	$	(531	)

NoInterest expense ~~revenue~~increased or$5,504 ~~cost~~for the three months ended March 31, 2022 from the comparative period of ~~sales~~2021 ~~were~~primarily ~~generated~~from ~~for~~accrued interest on the Company’s notes payable. The gain on forgiveness of debt of $3,029 for the three months ended ~~June~~March 3031, ~~2018~~2021 orwas ~~June~~a ~~30,~~result of ~~2017~~a ~~due~~decrease toof ~~the~~accounts ~~overall~~payable ~~reduction~~as ina ~~operations~~result of ~~the~~vendor ~~business~~adjustments.

~~Operating~~Comparison ~~Expenses~~of the Six Months Ended March 31, 2022 to the Six Months Ended March 31, 2021

~~Our expenses for the three months ended June 30, 2018 are summarized as follows in comparison to our expenses for the three months ended June 30, 2017:~~Revenue

	Three Months Ended June 30,
	2018		2017
General and administrative	$	2,998	$	14,037
Depreciation and amortization		-		-
Stock based compensation		-		-
Total operating expenses	$	2,998	$	14,037

No revenue or cost of sales were generated for the six months ended March 31, 2022 or March 31, 2021.

~~General and administrative~~Operating expense decreased by $11,039 for the three months ended June 30, 2018 from the comparative period of 2017 due to the scaling down of business. Depreciation and amortization expense, as well as stock-based compensation were $0 for the three months ended June 30, 2018 and June 30, 2017.Expenses

~~Comparison~~The ofCompany’s expenses for the ~~Nine~~six ~~Months~~months ~~Ended~~ended ~~June~~March 3031, ~~2018~~2022 toand ~~the~~2021, ~~Nine~~are ~~Months~~summarized ~~Ended~~as ~~June 30, 2017~~follows:

Revenue

	Six Months Ended March 31,
	2022		2021
General and administrative (including $8,049 and $27,578 of fees paid to related party)	$	98,624	$	48,215
Total operating expenses	$	98,624	$	48,215

NoThe increase ~~revenue~~in orgeneral ~~cost~~and ofadministrative ~~sales~~expenses ~~were generated~~ for the ~~nine~~six months ended ~~June~~March 3031, ~~2018~~2021 orcompared ~~for~~to the ~~nine~~six months ended ~~June~~March 3031, ~~2017~~2020 of $50,409 is due primarily to an increase in accounting and audit fees.

~~Operating~~Other Expenses

Our expenses for the nine months ended June 30, 2018 are summarized as follows in comparison to our expenses for the nine months ended June 30, 2017:

	Six Months Ended March 31,
	2022			2021
Interest Expense (including related party interest of $995 and $0)	$	16,833		$	4,880
Gain on forgiveness of debt		(1,539	)		(3,029	)
Total other expenses	$	15,294		$	1,851

	Nine Months Ended June 30,
	2018		2017
General and administrative	$	18,208	$	21,350
Depreciation and amortization		-		-
Stock based compensation		-		-
Total operating expenses	$	18,208	$	21,350

~~General and administrative~~Interest expense ~~decreased~~increased ~~by $3,142~~ for the ~~nine~~six months ended ~~June~~March 3031, ~~2018~~2022 from the comparative period of ~~2017~~2021 of $11,953 is due to anaccrued ~~overall~~interest ~~decrease~~due to the increase in ~~business~~interest ~~operations~~rate to 15% on the Company’s notes payable due to the default rate provisions. ~~Depreciation~~The gain on forgiveness of debt of $1,539 and ~~amortization~~$3,029, ~~expense~~for asthe ~~well~~six months ended March 31, 2022 and 2021, respectively, was a result of the reduction of accounts payable as ~~stock-based~~a ~~compensation~~result ~~were~~of vendor adjustments. The decrease of $01,490 is due to the timing of the related vendor adjustments.

13Liquidity and Capital Resources

~~Other~~Working ~~Expenses~~Capital

	Nine Months ended June 30,
	2018		2017
Interest Expense	$	3,094	$	634
Change in Fair Value of Convertible Debt		-		5,000
Total other expenses	$	3,094	$	5,634

The following table sets forth a summary of changes in working capital as of ended March 31, 2022 and September 30, 2021:

Interest expense increased from $634 to $3,094 for the nine months ended June 30, 2018 from the comparative period of 2017 due to additional accrued interest on the notes.

	As of
	March 31, 2022			September 30, 2021
Current Assets	$	180,206		$	261,152
Current Liabilities		620,309			587,337
Working capital	$	(440,103	)	$	(326,185	)

~~Liquidity~~The decrease in current assets of $80,946 is mainly due to a decrease in cash from the payment of outstanding bills and ~~Financial~~payment of a notes ~~Condition~~payable of $30,000 during the six months ended March 31, 2022. The increase in current liabilities of $32,972 is primarily due to a decrease in accounts payable and payments on notes payable during the six months ended March 31, 2022.

~~Working Capital Deficiency~~Cash Flows

		June 30, 2018		June 30, 2017
Current assets	$	17,359	$	2,991
Current liabilities		231,469		195,676
Working capital deficiency	$	(214,110)	$	(192,685)

The following table sets forth a summary of changes in cash flows for the six months ended March 31, 2022 and 2021:

The increase in current assets is mainly due to the receipt of a promissory note during the nine months ended June 30, 2018. The increase in current liabilities is due to transfer agent, filing and accounting fees incurred for the nine-month period ending June 30, 2018.

	Six Months Ended March 31,
	2022			2021
Net cash used in operating activities	$	(55,071	)	$	(60	)
Net cash used in financing activities		(30,000	)		-
Change in cash	$	(85,071	)	$	(60	)

~~Cash~~As of ~~Flows~~March 31, 2022, our cash balance was $176,081. The Company does not expect its current cash and operating income to be sufficient to meet its financial needs for continuing operations over the next twelve months.

	Nine Months Ended June 30,
	2018		2017
Net income (loss)	$	(21,302)	$	(26,984)
Net cash provided (used) in operating activities		(28,632)		(18,000)
Net cash used in investing activities		-		-
Net cash provided by financing activities		43,000		20,000
Increase (decrease) in cash	$	17,359	$	3,303

Net cash used in operations for the six months ended March 31, 2022 of $55,071 was mainly due to the net loss that was incurred during the period.

~~As of June 30, 2018, our~~Net cash ~~balance~~used ~~was~~in ~~$17,359.~~financing ~~The~~activities ~~Company~~for ~~does~~the ~~not~~six ~~expect~~months ~~its~~ended ~~current~~March ~~cash~~31, ~~and~~2022 ~~operating~~of ~~income~~$30,000 towas bedue ~~sufficient~~ to ~~meet~~payments ~~its~~on ~~financial needs~~notes ~~for~~payable ~~continuing~~during ~~operations over~~ the ~~next twelve months~~ period.

~~Net~~We may ~~cash~~need ~~used~~to inevaluate ~~operations for~~raising ~~the~~additional ~~nine~~capital ~~months~~through ~~ended~~the ~~June~~sale 30of equity securities, ~~2018~~through ~~was~~an ~~$28,632~~offering ~~mainly~~of ~~due~~debt securities or through borrowing from individuals. There can be no assurance that such a ~~decrease~~plan inwill ~~accounts~~be ~~payable~~successful.

We need to raise additional operating capital on an immediate basis. Although the expenses of our operations have been significantly reduced due to the termination of the license agreement as outlined in Note 3 of the financial statements, we need to still evaluate raising additional capital through the sale of equity securities, through an offering of debt securities or through borrowings from individuals. There can be no assurance that such a plan will be successful.15

~~As of the date of this~~Cash filing, we do not have enough sufficient cash on hand to cover our operating expenses through the next quarter. In the absence of any ongoing commercial operations, we need enough cash to pay certain outside professionals to maintain our compliance under the Securities Act of 1934. Management anticipates that it will require an additional $30,000 over the next twelve months to cover such costs.Requirements

14As of the date of this filing, we do not have sufficient cash on hand to cover our operating expenses through the next fiscal year. As of December 16, 2022, we had cash and cash equivalents of approximately $97,000. Our liquidity needs have been satisfied primarily from the issuance of notes payable. The notes payable are unsecured, matured on September 30, 2021, have not been extended, and are currently in default. There can be no assurance, however, that additional financing will be available or, if it is available, that we will be able to structure such financing on terms acceptable to us and that it will be sufficient to fund our cash requirements until we can reach a level of profitable operations and positive cash flows. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek additional financing. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.

~~Going~~Off-Balance ~~Concern~~Sheet Arrangements

~~The condensed consolidated~~We ~~financial~~have ~~statements~~no ~~contained~~off-balance insheet ~~this~~arrangements ~~report~~that have ~~been~~or ~~prepared~~are ~~assuming~~reasonably ~~that~~likely ~~the~~to ~~Company~~have ~~will continue as~~ a ~~going~~current ~~concern.~~or ~~The Company~~future ~~has~~effect ~~cumulative~~on ~~net~~our ~~losses~~financial ~~through June 30~~condition, changes ~~2018~~in offinancial $5condition,~~077,511,~~ asrevenues ~~well~~or ~~as negative cash flows of $28~~expenses,~~632~~ ~~from~~results ~~operating activities. The Company's cash and cash equivalents balance as~~ of ~~June 30~~operations, ~~2018 is $17~~liquidity,~~359.~~ ~~These~~capital ~~factors~~expenditures ~~raise~~or ~~substantial~~capital ~~doubt~~resources that ~~about~~is ~~the~~material ~~Company's ability~~ to ~~continue as a going concern~~stockholders.

~~While we will actively~~Effects ~~seek to identify sources~~ of liquidity, there are no assurances that such additional sources of liquidity can be obtained on terms acceptable to us on a commercially reasonable basis, or at all. These factors raise substantial doubt about our ability to continue as a going concern. Furthermore, our “going concern” and lack of commercial operations may make it more difficult for us to raise funds.Inflation

~~The consolidated financial~~We ~~statements~~ do not ~~include~~believe ~~any adjustments~~ that ~~may~~inflation behas ~~necessary~~had ~~should the Company be unable to continue as~~ a ~~going~~material ~~concern.~~impact ~~The Company’s continuation as a going concern is dependent~~ on ~~its~~our ability to obtain additional financing as may be required and ultimately to attain profitability. If the Company raises additional funds through the issuance of equity, the percentage ownership of current shareholders could be reduced, and such securities might have rights, preferences or privileges senior to its common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective business ~~endeavors or opportunities~~, ~~which~~ ~~could significantly and materially restrict its future plans for developing its business and achieving commercial~~ revenues~~. If~~ ~~the~~or ~~Company~~operating isresults ~~unable~~during ~~to obtain~~ the ~~necessary~~periods ~~capital, the Company may have to cease operations~~presented.

~~Off-Balance~~Critical Accounting ~~Sheet~~Policies ~~Arrangements~~and Estimates

WeOur unaudited ~~have~~condensed nofinancial ~~off-balance sheet~~statements ~~arrangements~~and ~~that~~accompanying notes have orbeen ~~are~~prepared ~~reasonably~~in ~~likely~~accordance towith ~~have~~United aStates ~~current~~generally oraccepted accounting ~~future~~principles ~~effect~~applied on ~~our~~a ~~financial~~consistent ~~condition,~~basis. ~~changes~~The preparation of unaudited condensed financial statements in conformity with U.S. ~~financial~~generally ~~condition,~~accepted ~~revenues~~accounting orprinciples ~~expenses,~~requires ~~results~~management to make estimates and assumptions that affect the reported amounts of ~~operations,~~assets and ~~liquidity~~liabilities, ~~capital~~the ~~expenditures~~disclosure orof ~~capital~~contingent ~~resources~~assets ~~that~~and isliabilities at the date of the unaudited condensed financial statements and ~~material~~the toreported ~~stockholders~~amounts of revenues and expenses during the reporting periods.

~~Effects~~We regularly evaluate the accounting policies and estimates that we use to prepare our unaudited condensed financial statements. A complete summary of ~~Inflation~~these policies is included in the notes to our unaudited condensed financial statements, along with the related notes contained in our Annual Report on Form 10-K as filed with the Securities & Exchange Commission. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

~~We do not believe that~~New ~~inflation~~accounting ~~has had a material impact on our business, revenues or operating results during the periods presented.~~standards

~~Critical~~For discussion of Recently Issued Accounting ~~Policies~~Pronouncements, see Note 1 to the unaudited condensed financial statements, “Nature of Operations, Basis of Presentation and ~~Estimates~~Summary of Significant Accounting Policies” in Part I, Item 1, of this Quarterly Report on Form 10-Q.

~~Our significant accounting~~ITEM ~~policies~~3. ~~are~~QUANTITATIVE ~~more~~AND ~~fully~~QUALITATIVE ~~described~~DISCLOSURES inABOUT ~~the~~MARKET ~~notes to our financial statements included herein for the nine months ended June 30, 2018.~~RISK

~~Newly Issued Accounting Pronouncements~~Not applicable.

~~See Note 1 to our financial~~ITEM ~~statements~~4. ~~included~~CONTROLS ~~herein~~AND ~~for the nine months ended June 30, 2018 for a discussion of Recently Issued Accounting Pronouncements.~~PROCEDURES

~~Item 3. Quantitative~~Evaluation ~~and~~of ~~Qualitative~~Disclosure ~~Disclosures~~Controls ~~about~~and ~~Market Risk~~Procedures

~~Not~~We maintain ~~applicable~~disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. At the end of the quarter ended March 31, 2022, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and the principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures.

~~Item 4. Controls and Procedures~~16

~~Evaluation~~We do not have an audit committee: While we are not currently obligated to have an audit committee, including a member who is an “audit committee financial expert,” as defined in Item 407 of ~~Disclosure~~Regulation ~~Controls~~S-K, under applicable regulations or listing standards; however, it is management’s view that such a committee is an important internal control over financial reporting, the lack of which may result in ineffective oversight in the establishment and ~~Procedures~~monitoring of internal controls and procedures.

~~We maintain disclosure~~Based ~~controls~~on ~~and~~this ~~procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934~~evaluation, aswe ~~amended,~~determined ~~or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure~~ that ~~such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer~~ as ~~appropriate, to allow timely decisions regarding required disclosure. At the end~~ of ~~the~~March ~~quarter ended June 30~~31, ~~2018~~2022, ~~we carried out an evaluation, under the supervision and with the participation of~~ our ~~management,~~disclosure ~~including~~controls ~~our principal executive officer~~ and ~~the~~procedures ~~principal~~were ~~financial~~not ~~officer,~~effective ~~of the~~due ~~effectiveness~~to of the ~~design and operation of our disclosure controls and procedures.~~ following:

15● We do not have a majority of independent directors on our board of directors, which may result in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

● We ~~do not~~ have an ~~audit committee:~~inadequate ~~While~~number weof ~~are~~personnel ~~not currently obligated~~ to ~~have~~properly animplement audit committee, including a member who is an “audit committee financial expert,” as defined in Item 407 of Regulation S-K, under applicable regulations or listing standards; however, it is management’s view that such a committee is an important internal control ~~over financial reporting, the lack of which may result in ineffective oversight in the establishment and monitoring of internal controls and~~ procedures.

~~Based~~● onDue ~~this~~to ~~evaluation, we~~the ~~determined~~size ~~that~~and aslack of ~~June~~resources ~~30,~~of ~~2018,~~ our ~~disclosure~~Company, ~~controls~~we ~~and~~have ~~procedures~~not ~~were~~fully ~~not~~developed ~~effective~~formal ~~due~~accounting topolicies ~~the~~and ~~following:~~procedures.

·● We dohave not ~~have~~properly acomplied ~~majority~~with ofall ~~independent~~aspects ~~directors on our board~~ of ~~directors,~~the ~~which~~Internal ~~may~~Control-Integrated ~~result~~Framework inissued ~~ineffective~~by ~~oversight in~~ the ~~establishment~~Committee ~~and~~of ~~monitoring~~Sponsoring Organizations of ~~required~~the ~~internal~~Treadway ~~controls~~Commission ~~and~~(COSO) ~~procedures~~in 2013.

·Limitations on WeEffectiveness ~~have an inadequate number~~ of ~~personnel~~Controls toand ~~properly implement control procedures.~~Procedures

·Our management, ~~Due~~including toour Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the ~~size~~objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and ~~lack~~the benefits of ~~resources~~controls must be considered relative to their costs. Because of ~~our~~the ~~Company~~inherent limitations in all control systems, weno evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not ~~fully~~limited ~~developed~~to, ~~formal~~the ~~accounting~~realities ~~policies~~that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

·Changes in ~~We have not properly complied with all aspects of the~~ Internal Control~~-Integrated~~ ~~Framework~~Over ~~issued~~Financial ~~by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013.~~Reporting

~~Limitations~~There were onno ~~Effectiveness~~changes ofin ~~Controls~~our internal control over financial reporting during the six months ended March 31, 2022 that have materially affected ~~and~~or ~~Procedures~~are reasonably likely to materially affect our internal control over financial reporting.

Our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.17

~~Changes~~PART II in– ~~Internal~~OTHER ~~Control Over Financial Reporting~~INFORMATION

~~There were no changes in~~ITEM ~~our~~1. ~~internal~~LEGAL ~~control over financial reporting during the three months ended June 30, 2018 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.~~PROCEEDINGS

16The Company knows of no material pending legal proceedings to which the Company or its Subsidiaries are a party or of which any of its properties, or the properties of its Subsidiaries, are the subject. In addition, the Company does not know of any such proceedings contemplated by any governmental authorities.

~~PART~~The Company IIknows –of ~~OTHER~~no ~~INFORMATION~~material proceedings in which any of the Company’s directors, officers or affiliates, or any registered or beneficial stockholder is a party adverse to the Company or its Subsidiaries or has a material interest adverse to the Company or its Subsidiaries.

~~Item 1~~ITEM 1A. ~~Legal Proceedings~~RISK FACTORS

~~The~~An investment in the Company’s ~~knows~~common stock involves a number of ~~no material~~very ~~pending~~significant ~~legal~~risks. ~~proceedings~~You toshould ~~which~~carefully consider the ~~Company~~risk orfactors included ~~its~~in ~~Subsidiaries~~the ~~are~~“Risk aFactors” ~~party~~section or of ~~which~~the ~~any~~Annual ofReport ~~its~~on ~~properties,~~Form or10-K for the ~~properties~~ ofyear ~~its~~ended ~~Subsidiaries~~September 30, ~~are~~2021 ~~the~~that ~~subject.~~was Infiled on ~~addition~~December 19, 2022, in addition to other information contained in those reports and in this quarterly report in evaluating the Company and ~~does~~its ~~not~~business ~~know~~before purchasing shares of ~~any~~its ~~such~~common ~~proceedings~~stock. ~~contemplated~~The byCompany’s business, operating results and financial condition could be adversely affected due to any ~~governmental~~of ~~authorities~~those risks.

~~The Company knows of no~~ITEM ~~material~~2. ~~proceedings~~UNREGISTERED inSALES ~~which~~OF ~~any~~EQUITY ofSECURITIES ~~the~~AND ~~Company’s~~USE ~~directors,~~OF ~~officers or affiliates, or any registered or beneficial stockholder is a party adverse to the Company or its Subsidiaries or has a material interest adverse to the Company or its Subsidiaries.~~PROCEEDS

~~Item 1A~~None. ~~Risk Factors~~

~~An investment in the Company’s~~ITEM ~~common stock involves a number of very significant risks~~3. ~~You~~DEFAULTS ~~should~~UPON ~~carefully~~SENIOR consider the risk factors included in the “Risk Factors” section of the Annual Report on Form 10-K for the year ended September 30, 2017 that was filed on January 12, 2018, in addition to other information contained in those reports and in this quarterly report in evaluating the Company and its business before purchasing shares of its common stock. The Company’s business, operating results and financial condition could be adversely affected due to any of those risks.SECURITIES

~~Item 2~~None. ~~Unregistered Sales of Equity Securities and Use Of Proceeds~~

~~None~~ITEM 4. MINE SAFETY DISCLOSURES

~~Item 3~~Not Applicable. ~~Defaults upon Senior Securities~~

~~None~~ITEM 5. OTHER INFORMATION

~~Item 4~~None. ~~Mine Safety Disclosures~~

~~Not Applicable.~~18

Item 5 6. ~~Other Information~~Exhibits

None.

Exhibit
Number	Description
(2)	Plan of acquisition, reorganization, arrangement, liquidation or succession
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
(3)	(i) Articles of Incorporation; and (ii) Bylaws
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
3.1.2	Certificate of Amendment to Articles of Incorporation (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.1.3	Certificate of Change (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
(4)	Instruments Defining the Rights of Security Holders, Including Indentures
4.1	Specimen Common Stock Certificate (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
4.1	Form of Registrant’s 10% Senior Convertible Promissory Note (incorporated by reference to our Registration Statement on Form 8-K filed on October 17, 2013)
(10)	Material Contracts
10.1	Convertible Promissory Note dated March 21, 2017 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on March 31, 2016.)
10.2	Convertible Promissory Note dated March 30, 2017 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on March 31, 2016.)
10.3	Convertible Promissory Note dated January 10, 2018 with Mediapark Investments Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.4	Convertible Promissory Note dated April 2, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.5	First Amendment to Convertible Promissory Note dated May 7, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.6	First Amendment to Convertible Promissory Note dated May 7, 2018 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.7	Promissory Note dated June 14, 2021 with Neil Reithinger (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.8	Promissory Note dated June 16, 2021 with Scott Lauer (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.9	Promissory Note dated June 30, 2021 with Utopia Capital, LLC (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on December 19, 2022)
10.10	Promissory Note dated July 6, 2021 with Church & Keeler, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.11	Promissory Note dated July 6, 2021 with Draper, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.12	Promissory Note dated July 6, 2021 with Happy David Walters (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.13	Promissory Note dated July 9, 2021 with Carriage House Capital, Inc. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.14	Promissory Note dated July 22, 2021 with John Walters Nick, Jr. (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.15	Promissory Note dated July 22, 2021 with Gary Goodman (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.16	Promissory Note dated July 26, 2021 with Stefan Galluppi (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.17	Promissory Note dated August 4, 2021 with Justin Schreiber (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.18	Promissory Note dated August 6, 2021 with Alexander Lim (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.19	Promissory Note dated August 12, 2021 with Aliunde Limited (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
10.20	Promissory Note dated September 28, 2021 with Neil Reithinger (incorporated by reference to our Registrant’s Annual Report on Form 10-K filed on December 19, 2022)
(31)	Rule 13a-14(a)/15d-14(a) Certification
31.1*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(32)	Section 1350 Certification
32.1*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(101)*	Interactive Data Files
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

*	Filed herewith.

**	Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

~~Item 6. Exhibits~~19

Exhibit
Number	Description
(2)	Plan of acquisition, reorganization, arrangement, liquidation or succession
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on September 5, 2013)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on March 20, 2014)
2.1	Articles of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
2.2	Agreement and Plan of Merger (incorporated by reference to our Registration Statement on Form 8-K filed on December 30, 2014)
(3)	(i) Articles of Incorporation; and (ii) Bylaws
3.1	Articles of Incorporation (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
3.1.2	Certificate of Amendment to Articles of Incorporation (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.1.3	Certificate of Change (incorporated by reference to our Registration Statement on Form 10-K filed on December 26, 2012)
3.2	Bylaws (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
(4)	Instruments Defining the Rights of Security Holders, Including Indentures
4.1	Specimen Common Stock Certificate (incorporated by reference to our Registration Statement on Form S-1 filed on December 29, 2008)
4.1	Form of Registrant’s 10% Senior Convertible Promissory Note (incorporated by reference to our Registration Statement on Form 8-K filed on October 17, 2013)
(10)	Material Contracts
10.1*	Convertible Promissory Note dated March 21, 2017 with Trius Holdings Limited
10.2*	Convertible Promissory Note dated March 30, 2017 with Sukh Athwal
10.3	Convertible Promissory Note dated January 10, 2018 with Mediapark Investments Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.4	Convertible Promissory Note dated April 2, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.5	First Amendment to Convertible Promissory Note dated May 7, 2018 with Sukh Athwal (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
10.6	First Amendment to Convertible Promissory Note dated May 7, 2018 with Trius Holdings Limited (incorporated by reference to our Registrant’s Quarterly Report on Form 10-Q filed on May 14, 2018)
(31)	Rule 13a-14(a)/15d-14(a) Certification
31.1*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
31.2*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(32)	Section 1350 Certification
32.1*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer
32.2*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer
(101)*	Interactive Data Files
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Filed herewith.

Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

18PEAK PHARMACEUTICALS, INC.

SIGNATURES

By:	/s/ Neil Reithinger
Neil Reithinger
Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
Date: December 19, 2022

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~20

PEAK PHARMACEUTICALS, INC.

By: /s/ Neil Reithinger Neil Reithinger Chief Executive Officer and Chief Financial Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) Date: August 13, 2018

Filing Compare · Retrieve Medical Holdings, Inc.